HC Wainwright Reduces Earnings Estimates for Precigen

Precigen, Inc. (NASDAQ:PGEN) – Equities research analysts at HC Wainwright reduced their FY2026 earnings estimates for shares of Precigen in a research report issued on Friday, November 15th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings of $0.01 per share for the year, down from their previous forecast of $0.02. HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.44) per share. HC Wainwright also issued estimates for Precigen’s FY2027 earnings at $0.22 EPS and FY2028 earnings at $0.39 EPS.

Other equities analysts have also recently issued reports about the stock. StockNews.com upgraded shares of Precigen to a “sell” rating in a report on Thursday, August 1st. JMP Securities decreased their price objective on shares of Precigen from $14.00 to $7.00 and set a “market outperform” rating for the company in a report on Thursday, August 15th. Two investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Precigen currently has a consensus rating of “Hold” and a consensus price target of $7.00.

Precigen Stock Down 7.1 %

Precigen stock opened at $0.82 on Monday. The company’s fifty day simple moving average is $0.92 and its 200-day simple moving average is $1.24. Precigen has a 12 month low of $0.78 and a 12 month high of $1.93. The stock has a market cap of $207.29 million, a P/E ratio of -1.49 and a beta of 1.68.

Institutional Investors Weigh In On Precigen

A number of large investors have recently bought and sold shares of the business. Geode Capital Management LLC boosted its holdings in Precigen by 4.8% in the third quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock worth $3,075,000 after purchasing an additional 149,829 shares in the last quarter. Barclays PLC boosted its holdings in Precigen by 190.4% during the third quarter. Barclays PLC now owns 189,353 shares of the biotechnology company’s stock valued at $179,000 after acquiring an additional 124,141 shares during the period. State Street Corp boosted its holdings in Precigen by 1.0% during the third quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock valued at $2,720,000 after acquiring an additional 29,253 shares during the period. Stifel Financial Corp raised its position in shares of Precigen by 94.9% during the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 15,680 shares during the last quarter. Finally, HighTower Advisors LLC raised its position in shares of Precigen by 186.8% during the third quarter. HighTower Advisors LLC now owns 192,144 shares of the biotechnology company’s stock valued at $179,000 after buying an additional 125,145 shares during the last quarter. 33.51% of the stock is currently owned by institutional investors.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.